Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
Source: View publication →
In the phase 3 PURPOSE 2 trial, twice-yearly subcutaneous lenacapavir was vastly superior to both estimated background incidence and daily oral F/TDF for HIV pre-exposure prophylaxis in cisgender men and gender-diverse individuals.
Key Findings
Study Design
Study Limitations
Clinical Significance
Lenacapavir represents a paradigm shift in HIV prevention. By extending the dosing interval to just twice a year, it dramatically lowers the behavioral barrier of daily pill-taking or every-two-month clinic visits. The near-complete protection demonstrated in PURPOSE 2, following similar results in PURPOSE 1 for cisgender women, positions lenacapavir as an incredibly potent tool in the global initiative to end the HIV epidemic, particularly for demographics experiencing high rates of incident HIV and poor adherence to daily regimens.
Historical Context
Since the FDA approval of daily oral F/TDF for PrEP in 2012, pre-exposure prophylaxis has fundamentally altered HIV prevention. However, real-world effectiveness has been heavily constrained by suboptimal adherence and persistence, particularly among marginalized populations. To address this, long-acting formulations were developed. Cabotegravir, given as an intramuscular injection every two months, was the first long-acting injectable approved for PrEP, demonstrating superiority over daily oral regimens in the HPTN 083 and 084 trials. Lenacapavir, a first-in-class HIV-1 capsid inhibitor with an ultra-long half-life, allows for subcutaneous administration every six months. The PURPOSE 1 trial established its near 100% efficacy in cisgender women in Africa. PURPOSE 2 was designed to confirm these findings in a globally diverse population of cisgender men and gender-diverse individuals, groups that continue to account for the majority of new HIV infections worldwide.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of lenacapavir differ from traditional oral PrEP agents like emtricitabine/tenofovir disoproxil fumarate (F/TDF), and how does this mechanism enable its unique dosing schedule?
Key Response
Emtricitabine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that terminate the viral DNA chain during replication. In contrast, lenacapavir is a first-in-class capsid inhibitor that targets the HIV-1 capsid protein directly. It disrupts multiple stages of the viral life cycle, including nuclear transport of the pre-integration complex, virus assembly, and release. This novel mechanism prevents cross-resistance with existing drug classes, and its high binding affinity and slow subcutaneous absorption allow for a long half-life, enabling the twice-yearly dosing schedule observed in the PURPOSE 2 trial.
A 24-year-old transgender woman presents to the clinic interested in switching from daily oral F/TDF to twice-yearly subcutaneous lenacapavir for PrEP. What specific baseline diagnostic testing is mandatory before initiating this long-acting injectable, and what are the clinical consequences of missing this step?
Key Response
Before initiating any long-acting PrEP agent, confirming the patient is definitively HIV-negative is critical. This typically requires both a fourth-generation HIV-1/2 Ag/Ab test and a sensitive HIV-1 RNA PCR assay to rule out acute, window-period HIV infection. Administering a long-acting antiviral like lenacapavir to a patient with unrecognized acute HIV can lead to monotherapy exposure for months, creating high selective pressure and resulting in irreversible multi-class drug resistance, severely limiting future antiretroviral therapy (ART) options.
The PURPOSE 2 trial specifically evaluated cisgender men and gender-diverse individuals. Considering the pharmacokinetic profile of lenacapavir, how might its interaction with gender-affirming hormone therapy (GAHT), such as estradiol, compare to the interactions seen with daily oral PrEP?
Key Response
Historically, there have been concerns that feminizing hormones might marginally lower tenofovir diphosphate concentrations in rectal tissues with daily F/TDF, though usually not below protective thresholds if adherence is perfect. Lenacapavir is metabolized primarily via CYP3A4, UGT1A1, and P-glycoprotein, but at clinical doses, it does not significantly induce or inhibit these pathways in a way that disrupts exogenous estrogen levels, nor does estrogen significantly alter lenacapavir exposure. This suggests lenacapavir offers robust efficacy without compromising the feminizing effects of GAHT, removing a major behavioral and pharmacological barrier for transgender women.
While the PURPOSE 2 trial demonstrates unparalleled efficacy for twice-yearly lenacapavir, a 6-month visit interval fundamentally alters the standard PrEP care model. How must primary care and sexual health clinics adapt their workflows to prevent this success in HIV prevention from paradoxically worsening the epidemic of other sexually transmitted infections (STIs)?
Key Response
Current PrEP guidelines emphasize quarterly (every 3 months) visits for HIV and comprehensive STI screening (gonorrhea, chlamydia, syphilis). Transitioning to a twice-yearly injection schedule drastically reduces routine clinical touchpoints. Attendings and clinic directors must implement hybrid care models—such as mailing at-home self-collection STI swabs at the 3-month mark, or establishing quick nurse/lab-only visits—to ensure that high-risk individuals are still screened and treated for STIs promptly, preventing asymptomatic transmission in their sexual networks.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The PURPOSE 2 trial utilized a recent-infection testing algorithm (RITA) on cross-sectional screening data to establish an estimated background HIV incidence (bHIV) as a counterfactual comparator. What are the primary methodological vulnerabilities of relying on recency assays to estimate a counterfactual, and how could an inaccurate False Recency Rate (FRR) bias the efficacy estimates?
Key Response
Using a bHIV counterfactual via RITA is an innovative solution to the ethical impossibility of a placebo arm in modern PrEP trials. However, recency assays are vulnerable to biological confounders such as elite control, naturally low viral loads, or prior use of antiretrovirals, which can make long-standing infections appear 'recent'. If the False Recency Rate (FRR) is underestimated, the calculated background incidence will be artificially inflated. This would result in the experimental intervention (lenacapavir) appearing falsely superior or having exaggerated relative efficacy when compared to this mathematically constructed control group.
When critically appraising the superiority of lenacapavir over daily oral F/TDF in the PURPOSE 2 trial, how should peer reviewers evaluate the role of medication adherence in the active comparator arm as a threat to construct validity?
Key Response
A classic challenge in PrEP trials is that daily oral F/TDF is biologically highly efficacious, but real-world adherence is frequently suboptimal. If the F/TDF arm in PURPOSE 2 suffered from low adherence, lenacapavir's statistical superiority may reflect a behavioral advantage (circumventing the need for daily pill-taking) rather than superior intrinsic pharmacological potency. A rigorous reviewer would demand detailed intracellular tenofovir-diphosphate concentration data from the F/TDF arm to stratify the comparison by actual adherence levels, clarifying whether lenacapavir is pharmacologically superior or strictly structurally superior.
In light of the PURPOSE 2 trial findings, what specific implementation challenges and clinical caveats must guideline bodies like the CDC and WHO address before designating twice-yearly lenacapavir as a Category 1A preferred PrEP option alongside oral F/TDF and injectable cabotegravir?
Key Response
While the efficacy data strongly supports a Category 1A recommendation, guidelines must address several systemic and clinical challenges. These include the management of the 'pharmacokinetic tail' (the prolonged period of sub-therapeutic drug levels if a patient discontinues injections, which risks resistance if HIV is acquired during this window), protocols for transitioning between lenacapavir and oral PrEP, requirements for RNA-based screening to detect breakthrough infections, and the practicalities of global cold-chain and cost accessibility to ensure equitable distribution.
Clinical Landscape
Noteworthy Related Trials
iPrEx Trial
Tested
Oral daily TDF/FTC
Population
HIV-negative men and transgender women who have sex with men
Comparator
Placebo
Endpoint
HIV incidence
DISCOVER Trial
Tested
Oral daily F/TAF
Population
HIV-negative MSM and transgender women at risk for HIV
Comparator
Oral daily F/TDF
Endpoint
HIV incidence
HPTN 083 Trial
Tested
Long-acting injectable cabotegravir every 8 weeks
Population
HIV-negative MSM and transgender women
Comparator
Oral daily TDF/FTC
Endpoint
HIV incidence
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis